Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The ability for patients with COPD to exercise is limited due to the deterioration of their
lung function. NVA237 is being developed to treat COPD. This study is designed to look at how
well NVA237 improves the ability to exercise in patients with moderate to severe COPD.